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Available online 28 September 2017Zika virus (ZIKV) has become a global public health emergency due to its rapidly expanding range and its ability
to cause severe congenital defects such as microcephaly. However, there are no FDA-approved therapies or vac-
cines against ZIKV infection. Through our screening of viral entry inhibitors, we found that chloroquine (CQ), a
commonly used antimalarial and a FDA-approved drug that has also been repurposed against other pathogens,
could significantly inhibit ZIKV infection in vitro, by blocking virus internalization. We also demonstrated that
CQ attenuates ZIKV-associated morbidity and mortality in mice. Finally, we proved that CQ protects fetal mice
from microcephaly caused by ZIKV infection. Our methodology of focusing on previously identified antivirals
in screens for effectiveness against ZIKV proved to be a rapid and efficient means of discovering new ZIKV ther-
apeutics. Selecting drugs that were previously FDA-approved, such as CQ, also improves the likelihood that they
may more quickly reach stages of clinical testing and use by the public.
© 2017 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Antiviral effects1. Introduction
Zika virus (ZIKV) is a single-stranded RNA virus primarily transmit-
ted by mosquitos and closely related to dengue virus (DENV), another
member of the Flaviviridae family (Musso and Gubler, 2016). It was
first identified in 1947 from a rhesus monkey in the Zika forest ofSystems Medicine, Institute of Basic
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rica and Asia, and ZIKV strains became classified as belonging to either
the African or Asian lineages (Haddow et al., 2012). Since 2013,
human infection with the Asian lineage of ZIKV in the South Pacific
and the Americas (Gulland, 2016) has been reported to be associated
with Guillain-Barré syndrome (GBS), meningoencephalitis andMedical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College,
en and Biosecurity, Beijing Institute ofMicrobiology and Epidemiology, Beijing 100071, China.
S Center for Excellence inBrain Science and Intelligence Technology, Institute ofGenetics and
al Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing
icrobiology, Immunology and Molecular Genetics, University of California, Los Angeles, CA
u@genetics.ac.cn (Z. Xu), gcheng@mednet.ucla.edu (G. Cheng).
-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
190 C. Li et al. / EBioMedicine 24 (2017) 189–194congenitalmicrocephaly (Araujo et al., 2016; Brasil et al., 2016; Driggers
et al., 2016; Rasmussen et al., 2016). ZIKV was also found to be sexually
transmissible (D'Ortenzio et al., 2016), and infectionwas found to cause
male infertility in susceptiblemice (Govero et al., 2016;Ma et al., 2016).
We and others were able to developmousemodels inwhich ZIKV infec-
tion in utero could lead to microcephaly (Cugola et al., 2016; Li et al.,
2016; Miner et al., 2016). Given that ZIKV can be acquired by sexual ac-
tivity even with asymptomatic ZIKV carriers (Hills et al., 2016), and the
extensive range of the mosquito vectors and of human travel, this virus
has become a global threat.
There are currently no FDA-approved drugs available for the preven-
tion or treatment of ZIKV infection or its associated risk of congenital de-
fects. Although vaccines are in early trials for effective ZIKV prevention,
their development and manufacture is a rigorous and time-consuming
process. Antibody-based therapies have shown promise in the mouse
model, however these drugs are expensive and in limited supply, and
their safety has yet to be validated in humans. Drug repurposing screens
have been shown in the past to be an efficient approach to speeding up
drug development, and should be given prioritywhen strategies are de-
vised against new emerging viruses (Nabel and Zerhouni, 2016). These
screens led to the discovery of potential new therapies for Entamoeba
histolytica infection (Debnath et al., 2012), hepatitis C virus (HCV) infec-
tion (He et al., 2015) and also ZIKV (Barrows et al., 2016; Xu et al., 2016).
During the 2014 Ebola virus (EBOV) outbreak in West Africa, re-
searchers were desperate to find a cure that could rapidly reach those
in need. Multiple FDA-approved drugs were screened for possible
repurposing as EBOV treatments (Johansen et al., 2013, 2015;
Kouznetsova et al., 2014). We decided to perform a similar screen of
16 EBOV inhibitors for their potential use against ZIKV. As these drugs
have already passed strict FDA guidelines for human safety, any candi-
dates with promising efficacy against ZIKV might be approved more
rapidly than novel drugs as anti-ZIKV therapies. Of note, we have
found that one of the drugs, chloroquine can inhibit ZIKV infection effi-
ciently in vitro, in agreement with previous finding that CQ could inhibit
ZIKV (MR766 strain and Brazilian strain) infection in Vero, human brain
microvascular endothelial cells (hBMEC) and hNPC cells (Delvecchio et
al., 2016). Our results further demonstrated that CQ suppresses ZIKV in-
fection in mouse models in vivo and protects embryonic brains from
ZIKV infection and its associated microcephaly.
2. Materials and Methods
2.1. Mice and Ethics Statements
A129 mice (IFN-α/β receptor deficient) were a gift from Professor
Qi-Bin Leng (Institut Pasteur of Shanghai, Chinese Academy of Sciences,
China). ICR mice were bought from Vital River Laboratory (Beijing,
China) and BALB/c and Kunming mice were bought from Jackson Labo-
ratory (Bar Harbor, ME) and then bred in our core animal facility. All ex-
periments related to animals were conducted according to protocols
approved by the Animal Experiment Committee of the Laboratory Ani-
mal Center, Academy of Military Medical Sciences, China (IACUC-13-
2016-001).
2.2. Virus, Cells and Reagents
ZIKV strains (GZ01, GenBank: KU820898; FSS13025, GenBank:
JN860885) used in this study were described in our previous work
(Deng et al., 2016; Zhang et al., 2016). BHK-21, Huh7 and Vero cells
were bought from ATCC and cultured in DMEM media (37 °C, 5%
CO2). All media were supplemented with 10% FBS (ExCell Bio, Jiangsu),
100 units/ml penicillin, and 50 μg/ml streptomycin. NITD008 was pro-
vided by Dr. Pei-Yong Shi (Novartis Institute for Infectious Diseases).
Chloroquine (Sigma, C6628) and other molecules were purchased
from Sigma or Sangon (Shanghai, China).2.3. RNA Isolation and Real Time Quantitative PCR
Total RNA from cell supernatants was extracted with the EasyPure
Viral DNA/RNA Kit (TransGen Biotech, Beijing). Viral RNA copies were
detected by real time quantitative PCR (qRT-PCR) (Johnson et al.,
2005). ZIKV primers were described previously (Deng et al., 2016).
2.4. ZIKV Internalization Assay and Plaque Assay
ZIKV internalization assay and plaque assay were performed as de-
scribed previously (Talarico et al., 2005). Briefly, BHK-21 cells seeded
in 12 well plates were infected with ZIKV (200 PFU) at 4 °C for 1 h.
Cells were then washed with PBS and incubated at 37 °C for 1 h to
allow virus internalization. Cells were washed with PBS and treated
with citric acid buffer (pH 3.0) to inactivate non-internalized viruses.
Media containing 2% FBS and 1% agarwas immediately added for plaque
assay as described previously (Li et al., 2017). Viral plaques were count-
ed at 4 dpi.
2.5. ZIKV Replicon Assay
The ZIKV replicon assay was conducted as described previously (Liu
et al., 2013; Xie et al., 2016). Briefly, in vitro transcribed RNA was
transfected with Lipofectamine 2000 reagent (Thermo Fisher) into
BHK-21 cells seeded in 24 well plates. 6 hour post transfection (hpt),
CQ was added to the media. 48 hpt, the renilla luciferase activity in
cell lysates was measured with a microplate reader (Promega).
2.6. ZIKV Infection in Mice
3–4week-old BALB/cmice (female) or A129micewere treatedwith
CQ or a control intragastrically (i.g.) 6 h before ZIKV infection and once
daily for the following 5 days (A129mice).Micewere infected intraper-
itoneally (i.p.) with ZIKV strain GZ01/2016. ZIKV RNA copies in serumat
indicated time points were measured by qRT-PCR as described previ-
ously (Li et al., 2017).
For neonatal mouse infection, 20 μl DMEM containing 100 PFU of
ZIKV was injected intracerebrally to 1-day-old Kunming mice (Deng et
al., 2016). 20 mg/kg CQ was administrated by s.c. route to the mother
mice as previously described (Keyaerts et al., 2009).
For the microcephaly model, 1 μl of ZIKV GZ01 virus stock (3.5
× 105 PFU/ml) or culture medium was injected transplacentally into
one side of the cerebroventricular space/lateral ventricle (LV) of E13.5
ICR mouse brains and inspected 5 days later as described previously
(Li et al., 2016; Wang et al., 2017). For each pregnant dam, around one
half of littermates were injected with ZIKV.
2.7. Immunohistochemistry and Antibodies
For cryosections, tissues were fixed in 4% PFA, dehydrated in 30% su-
crose, and frozen in TFM (tissue freezingmedium). Sections (thickness:
E18.5, 40 μm)were used for immunofluorescence staining as described
previously (Li et al., 2016). The antibodies used for immunostaining
were anti-ZIKV serum from a patient (1:1000), Activated-caspase3
(Abcam, ab2302, 1:1000), Phospho-Histone 3 (P-H3) (Abcam,
ab10543, 1:1000), Sox2 (Abcam, ab97959, 1:1000), Tbr2 (Miilipore,
ab15894, 1:1000), NeuN (Abcam, ab104224, 1:1000), and Tbr1
(Abcam, ab31940, 1:500). Nuclei were stained with 4′, 6-diamidino-2-
phenylindole (DAPI, Invitrogen).
2.8. Nissl Staining
Brain slices were stained with 0.1% toluidine blue for 5 min and
dehydrated in turn by 70%, 96%, and 99% ethanol (45 s, twice for
each). Finally, slices were hyalinized by Xylene for 5 min before being
sealed with neutral balsam.
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Slices were imaged on an LSM 700 (Carl Zeiss) confocal microscope,
and the images were analyzed and qualified with Zen (Blue edition) or
ImageJ as described previously (Li et al., 2016).
2.10. Statistical Analysis
Prism software (GraphPad)was used to analyze the data. All data are
shown as mean ± SEM from three repeat assays. *p ≤ 0.05, **p ≤ 0.01,
***p ≤ 0.001, unpaired student t-test.
3. Results
Of the 16 EBOV entry inhibitors reported previously (Johansen et al.,
2013, 2015; Kouznetsova et al., 2014), we found that the FDA-approvedFig. 1. CQ inhibits ZIKV entry in vitro and in vivo. (A) BHK-21 cellswere treated for 12 hwith 10 μ
control; Ribavirin was used as a negative control). The cells were then infected by ZIKV (GZ01/2
infection. 5 molecules (chloroquine, clomiphene, amodiaquine, alverine and sertraline) were i
infected with ZIKV for 1 h. ZIKV in cell supernatants were detected with qRT-PCR at 48 hpi.
Huh7 cells (D) are indicated. (E–G) Inhibitory effects of CQ on binding to Vero cells (E), ZIKV i
for 12 h, then were infected with ZIKV (E, 200 PFU/well; F, MOI = 1) at 4 °C for 1 h. (F) Then
internalized ZIKV (F) were detected using plaque assay and qRT-PCR, respectively. (G) ZIKV
treat cells for 48 h. Renilla luciferase activity was measured with a microplate reader. All dat
***P ≤ 0.001, unpaired student t-test.drugs chloroquine (CQ), clomiphene, amodiaquine, alverine and sertra-
line could inhibit the early stages of ZIKV infection (Fig. 1A). Consistent
with the fact that ribavirin is a polymerase inhibitor, it did not disrupt
ZIKV entry in our experiment, therefore it served as a negative control
(Fig. 1A). Since clomiphene cannot be given safely to pregnant women
(Legro et al., 2007), and amodiaquine, alverine and sertraline were
less effective inhibitors, we focused on CQ, which had an efficacy similar
to the known 25-hydroxycholesterol (25HC) ZIKV entry inhibitor (Li et
al., 2017). The IC50 of CQ against ZIKV (GZ01, a recent Asian lineage
strain (Zhang et al., 2016)) is about 4.15 μM in Vero cells and 1.72 μM
in Huh7 cells (Fig. 1B-C), while there was no cytotoxicity induced by
CQ even at 10 μM (Fig. S1) (Kouznetsova et al., 2014). CQ also inhibits
the ZIKV FSS13025 strain (old Asian lineage), with an IC50 of 2.72 μM
in Huh7 cells (Fig. 1D). In order to detect which step of the ZIKV life
cycle is inhibited by CQ, an internalization assay was performed as pre-
viously described (Talarico et al., 2005) using the RNA synthesisMof 16 individual compounds known to inhibit entry by EBOV (25HCwas used as positive
016 strain, 200 PFU/well) for 1 h and plaque assaywas performed to compare the levels of
dentified to inhibit ZIKV infection. (B–D) Cells were pretreated with CQ for 12 h and then
The IC50 of CQ on ZIKV (GZ01) in Vero (B) or Huh7 cells (C), or on ZIKV (FSS13025) in
nternalization (F) and RNA synthesis (G) are shown. (E-F) Cells were pretreated with CQ
cells were washed once by PBS and incubated at 37 °C for 1 h. The bound ZIKV (E) and
replicon RNA was transfected into BHK-21 cells. 6 h later, CQ or NITD008 were used to
a are shown as mean ± SEM from three independent experiments, *P ≤ 0.05, **P ≤ 0.01,
Fig. 2. CQ protects against ZIKV infection in mouse models. (A) Antiviral effect of CQ on
ZIKV infection in BALB/c mice (A) and A129 mice (B–C). 100 mg/kg of CQ was
administrated to mice i.g. 6 h before ZIKV infection i.p. (105 PFU/mouse for BALB/c, 103
PFU/mouse for A129 experiment). Viremia was determined at 1 (A), 3 or 5 (B–C) dpi as
indicated. (D) Improved survival of ZIKV-infected suckling neonatal mice after CQ was
given to breastfeeding mothers. 1-day-old neonatal mice were infected intracerebrally
with ZIKV (100 PFU/mouse, GZ01 strain). Kunming mother mice were administrated CQ
subcutaneously (s.c.) at 0, 12 or 24 hpi. CQ continued to be given daily to the mothers
for another 10 days. Survival of ZIKV-infected neonatal mice was followed until 30 dpi.
Median values for 4–7 mice for experiments in A–C are shown. *P ≤ 0.05, **P ≤ 0.01, ***P
≤ 0.001, unpaired student t-test. Log-Rank (Mantel-Cox) test were used in D (PBS, n =
10; 0 hpi, n= 20; 12 hpi, n= 18; 24 hpi, n= 8).
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suppressed ZIKV internalization effectively, while NITD008 did not
(Fig. 1F). However, CQ did not interfere with ZIKV binding to cells or
RNA synthesis (Fig. 1E, G).
Next, we tested the ability of CQ to protect against ZIKV infection in
vivo. 3–4 week-old immunocompetent BALB/c mice were treated with
CQ (100mg/kg) by intragastric administration (i.g.) 6 h before ZIKV in-
fection by the intraperitoneal (i.p.) route (GZ01 strain, 105 PFU/mouse).
CQ treatment significantly suppressed ZIKV infection in mice compared
to the PBS control at 1 day post-infection (dpi) (Fig. 2A). We then used
the IFN-α/β receptor (IFNAR)-deficient A129 mouse model (Dai et al.,
2016; Lazear et al., 2016) to further evaluate the protective effects of
CQ on ZIKV infection. A129 mice were treated with PBS or CQ (i.g.,
100 mg/kg) 6 h before ZIKV infection (GZ01 strain, 103 PFU/mouse),
and daily for the following 5 days. Viremia was measured at 3 and
5 dpi, and it was found to be significantly reduced in CQ-treated mice
(Fig. 2B–C). Since CQ transmitted through breastmilk was found to in-
hibit human coronavirus OC43 infection in newborn mice through ma-
ternal milk (Keyaerts et al., 2009), we then tested the effects of CQ on
ZIKV infection in a neonatal mouse model (Deng et al., 2016) (Fig.
2D).We found that CQ treatment ofmothermice could improve surviv-
al of ZIKV-infected suckling neonatal mice by about 90% (Fig. 2D). If CQ
was administrated at 12 hour post infection (hpi), this protective effect
was reduced, and became completely absent when postponing CQ
treatment to 24 hpi. These results showed that CQ can suppress ZIKV
mouse infection.
Previously, we have shown that 25HC and convalescent serum from
a patient who recovered from ZIKV infection both protected embryonic
mice from ZIKV infection and its associated microcephaly (Li et al.,
2017; Wang et al., 2017). Here we adopted the same model to investi-
gate the effect of CQ on littermate embryos. ZIKV (~350 pfu) or culture
medium was injected into the cerebroventricular space in the brains of
embryonic day 13.5 (E13.5) ICR mice. Pregnant mice were treated with
PBS (Veh) or CQ (i.g., 100 mg/kg) 6 h before infection of the embryonic
brains, and then once a day from E13.5 to E18.5. The mice were
sacrificed and inspected at E18.5. First, we investigated whether CQ
could protect mice from microcephaly caused by ZIKV infection. Com-
pared to the mock-infected or ZIKV-infected CQ-treated groups, the av-
erage brain sizes of ZIKV-infected but untreatedmice were significantly
smaller (Fig. 3A). In addition, the brains of thosemice had a significantly
thinner cortex compared to the brains of uninfected or CQ-treated mice
(Fig. 3B). The reduced thickness of different layers of cortex was con-
firmed by immunostaining with NeuN and Tbr1 antibodies (Fig. 3B
and Fig. S2).
We next exploredwhether CQ treatment could suppress ZIKV infec-
tion in fetal brains. Immunostaining with an anti-ZIKV serum showed
that the embryonic brains infected with ZIKV and treated with CQ had
a dramatically reduced burden of ZIKV compared to untreated infected
brains (Fig. 3C). Similarly, the intensity of cells positive for the activated
form of Caspase 3, an indicator of apoptosis, was also reduced substan-
tially after CQ treatment (Fig. 3D). These findings indicate that CQ can
significantly reduce ZIKV infection and its associated apoptotic effects
in the fetal brain, which has been shown previously to be a contributing
factor in the development of microcephaly (Li et al., 2016; Wang et al.,
2017).
The infection of neuronal progenitor cells (NPCs) and the dysregula-
tion of their proliferation and differentiation may also contribute to
thinner VZ/SVZ cortical layers and microcephaly (Li et al., 2016; Wang
et al., 2017). We investigated whether CQ could prevent this effect on
NPC proliferation after ZIKV infection. As shown in Fig. 3E, cells positive
for phosphorylated histone H3 (P-H3, a marker for cells in M-phase)
were significantly reduced in ZIKV-infected brains. Surprisingly, these
cells were rescued by CQ therapy. Similarly, the reduction in Sox2+
(NPC marker) and Tbr2+ (intermediate/basal progenitor cell marker)
cells were also reversed in those treated with CQ (Fig. 3F). These find-
ings correlate with changes in the cortical layer thickness and overallsize of ZIKV-infected brains. Therefore, CQ treatment protects embryon-
ic mice from ZIKV infection and its associated microcephaly.
4. Discussion
Recently, Xu et al. performed a screen of ~6000 compounds ap-
proved or under investigation by the FDA, and found that ~3% (173/
6096) could suppress ZIKV infection in neural cells (Xu et al., 2016).
Similarly, Barrows et al. tested 700 FDA-approved drugs and found
that 20 (~3%) had inhibitory effects on ZIKV replication in vitro
(Barrows et al., 2016; Xu et al., 2016). However, in vivo testing of
these drugs has not yet to be performed.We chose to begin our screen-
ing with EBOV inhibitors, which yielded a much higher percentage of
promising ZIKV therapeutics (~31%, 5/16).
Recently, Bullard-Feibelman et al. reported that the FDA-approved
anti-hepatitis C drug sofobuvir can also inhibit ZIKV infection in vitro
and in vivo (Bullard-Feibelman et al., 2017). However, its ability to pre-
vent ZIKV-associated microcephaly remains unclear, and the drug is
also very expensive. CQ is a widely used anti-malarial drug, and was
found to have no toxic effects in pregnant women or their infants. Pre-
viously, there were two clinical trials to investigate the antiviral effects
of CQ on DENV infection (Borges et al., 2013; Tricou et al., 2010). Pa-
tients were given CQ for 3 days beginning 72 h after infection by
DENV in both trials. The results showed that CQ did not reduce the du-
ration of viral infection, but could reduce the chance of dengue hemor-
rhagic fever (Tricou et al., 2010), as well as decrease patients' perceived
intensity of pain and improve their daily activity performance (Borges
et al., 2013). Our results demonstrated that CQ can prevent ZIKV-
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fection (0 or 12 hpi), but it has no antiviral effect when administrated
at 24 hpi (Fig. 2D). Together, these findings provide valuable informa-
tion for setting up future clinical trials using CQ against ZIKV infection.
In addition, thewidespread availability of CQ, as well as its safety profile
in pregnancy, are important benefits for its global distribution. Through
RNASeq, we detected the induction of multiple cytokines in the embry-
onic brain upon ZIKV infection, and suggest that this strong immune re-
sponse is likely to play an important role in the neuronal cell death that
leads to microcephaly (Li et al., 2016). CQ may be protecting mice from
these ZIKV-induced inflammatory changes at a critical stage in their
brain development, although thiswould need to be further investigated.
We also have noticed that it should be investigated more extensively
before using CQ as for possible ZIKV therapy in humans.
Ourmethodology of restricting screens for ZIKV therapeutics to FDA-
approved EBOV-inhibitors was both efficient and more likely to allowFig. 3.CQprotects embryonic brains fromZIKV infection andmicrocephaly. Littermate embryon
daily with CQ or vehicle until E18.5. (A) Images of brains and Nissl staining of coronal sections.
ZIKV+Veh: n=6/3, ZIKV+CQ: n=8/4. CP: cortical plate, SP: subplate, IZ: intermediate zone,
ZIKV antiserum (green) and DAPI (blue). Right panel: Quantification of relative intensity. n= 7
DAPI (blue). Right panel: quantification of relative intensity.N=7/3 for each. (E) Images of cort
H3+ cells. Mock+Veh: n=7/4,Mock+CQ: n=8/3, ZIKV+Veh: n=5/3, ZIKV+CQ: n=5
quantification of the density of Sox2+ cells and Tbr2+ cells in the cortices. Mock+ Veh: n=8
10/5 (Sox2+), 10/5 (Tbr2+); ZIKV+CQ: n=10/5 (Sox2+), 10/5 (Tbr2+). All data aremeans
ns: not significant. n: number of slices/different brains. Scale bar for 1 mm (A), 100 μm (B–F).promising candidates, like CQ, to quickly reach clinical trials. Such a
strategy is important to rapidly bring to market therapeutics which
could help prevent or relieve symptoms of ZIKV infection, and should
also be considered for other emerging infections in the future.
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